Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Silo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment | 1 | Contract Pharma | ||
Mi | Hoth Therapeutics, Inc: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | 243 | JCN Newswire | NEW YORK, June 25, 2025 - (ACN Newswire) - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
Mi | Silo Pharma to form JV with Hoth Therapeutics for obesity treatment | 1 | Seeking Alpha | ||
Mi | Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment | 2 | Investing.com | ||
Mi | Hoth Therapeutics, Silo Pharma Launch JV To Commercialize VA-Invented Obesity Drug | - | RTTNews | ||
Mi | Silo Pharma, Inc.: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | 134 | GlobeNewswire (Europe) | Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental... ► Artikel lesen | |
11.06. | Silo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears | 400 | GlobeNewswire (Europe) | SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
05.06. | Silo Pharma stock surges on Bitcoin reserve move | 1 | Investing.com | ||
SILO PHARMA Aktie jetzt für 0€ handeln | |||||
05.06. | Silo Pharma allocates $1 million to Bitcoin holdings | 1 | Investing.com | ||
05.06. | Silo Pharma, Inc.: Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset | 265 | GlobeNewswire (Europe) | SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
21.05. | Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug | 1 | Seeking Alpha | ||
21.05. | Silo Pharma advances PTSD treatment with new drug-device study | 2 | Investing.com | ||
21.05. | Silo Pharma treibt PTBS-Behandlung mit neuer Medikamenten-Geräte-Studie voran | 5 | Investing.com Deutsch | ||
21.05. | Silo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 | 231 | GlobeNewswire (Europe) | SARASOTA, FL, May 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
16.05. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.05. | Silo Pharma, Inc.: Silo Pharma Announces Closing of $2 Million Public Offering | 1 | GlobeNewswire (USA) | ||
15.05. | Silo Pharma sets public offering at $0.60 per share and warrant | 1 | Investing.com | ||
15.05. | Silo Pharma announces pricing of $2 million public offering | 3 | Seeking Alpha | ||
15.05. | Silo Pharma, Inc.: Silo Pharma Announces Pricing of $2 Million Public Offering | 1 | GlobeNewswire (USA) | ||
14.05. | Silo Pharma treibt PTBS-Behandlungsstudie mit Veloxity Labs voran | 1 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
ILLUMINA | 80,30 | -0,91 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
EDITAS MEDICINE | 1,924 | -1,00 % | Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? | ||
BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
TEMPUS AI | 56,44 | -0,67 % | Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? | ||
SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
CARDIOL THERAPEUTICS | 1,304 | +8,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen |